Home
This site is intended for healthcare professionals

Precision Decisions in Metastatic Prostate Cancer: Key Clinical Summary Module 2

This is a summary of a presentation by Dr. Alicia Morgans, MD, MPH, which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Pfizer. This online education program has been designed for for US Healthcare Professionals only.

PARP Inhibitor–Based Strategies in Metastatic Prostate Cancer: Key Clinical Summary

PARP inhibitors (PARPi) have established a biomarker-driven role in metastatic prostate cancer, while combination strategies with androgen receptor pathway inhibitors (ARPIs) are expanding their use across both metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Treatment selection should integrate disease stage, DNA repair alterations, prior therapy, expected efficacy, toxicity, and the specific evidence supporting each regimen.

Biological rationale for PARPi + ARPI combinations

  • Androgen receptor (AR) signaling contributes to transcription of DNA repair genes, creating biological crosstalk between AR signaling and homologous recombination repair (HRR).
  • AR-pathway inhibition may reduce homologous recombination capacity and induce a BRCA-like state, potentially increasing tumour dependence on PARP-mediated repair.
  • PARP-1 can also function as a co-activator of AR transcription, providing a rationale for dual pathway inhibition.
  • This synthetic-lethal relationship supports combining PARPi with ARPIs, particularly in tumours with pre-existing HRR deficiency, although clinical benefit varies substantially by gene and regimen.

What the clinical evidence shows

PARPi monotherapy: biomarker selection remains important

  • PROfound established the principle of selecting patients with HRR alterations for PARPi treatment in mCRPC after prior ARPI therapy. Benefit was greatest in patients with BRCA1/2 alterations.
  • TRITON3 similarly demonstrated benefit with PARPi therapy in HRR-altered mCRPC, with the strongest effect observed in BRCA-mutated disease.
  • ATM alterations appear to confer less consistent benefit than BRCA1/2 alterations. Therefore, an HRR alteration should not automatically be treated as equivalent across genes.

PARPi + ARPI in first-line mCRPC

Several phase 3 studies support combination approaches, but the populations and magnitude of benefit differ:

  • Olaparib + abiraterone (PROpel): demonstrated radiographic progression-free survival (rPFS) benefit in an all-comer first-line mCRPC population, with the greatest benefit concentrated in patients with BRCA mutations. Final overall survival did not demonstrate a statistically significant benefit in the overall population.
  • Niraparib + abiraterone (MAGNITUDE): benefit was demonstrated in HRR-altered disease, particularly BRCA-mutated disease. The non-HRR cohort was stopped for futility, reinforcing the importance of biomarker selection.
  • Talazoparib + enzalutamide (TALAPRO-2): demonstrated rPFS benefit in both the overall population and HRR-deficient disease, with particularly meaningful activity in BRCA-mutated tumours and subsequent mature survival data supporting the combination.

These studies should not be compared using point estimates alone, because they enrolled different populations, used different comparators and regimens, and had different follow-up periods.

Selecting patients for combination therapy

Consider PARPi-based combinations when:

  • The patient has an actionable HRR alteration, particularly BRCA1/2, where the evidence for benefit is strongest.
  • The patient is at an appropriate disease stage for a regimen supported by clinical evidence and local prescribing guidance.
  • The potential incremental benefit justifies the additional treatment burden and toxicity.
  • Germline and somatic testing have been appropriately considered, as either may identify clinically relevant alterations.

For alterations such as ATM, benefit may be attenuated or less certain. Treatment should therefore be guided by the specific trial evidence and regimen rather than by the presence of an HRR alteration alone.

PARPi combinations in mCSPC: distinguish evidence from approved indications

  • AMPLITUDE demonstrated benefit with niraparib + abiraterone/prednisone in HRR-altered mCSPC, with particularly relevant benefit in BRCA2-mutated disease.
  • As of September 2026, in the US, niraparib/abiraterone acetate with prednisone is approved for adults with deleterious or suspected deleterious BRCA2-mutated mCSPC.
  • TALAPRO-3 demonstrated a substantial rPFS benefit with talazoparib + enzalutamide in HRR-altered mCSPC. However, these findings should be distinguished from the current US indication: talazoparib + enzalutamide is approved for HRR gene-mutated mCRPC, not mCSPC.
  • Treatment decisions should therefore distinguish emerging or recently reported trial evidence from current approved indications and should follow the applicable prescribing information and local guidance.

Sequencing: avoid unnecessarily delaying an effective PARPi strategy

A key sequencing consideration is attrition: reserving a potentially effective PARPi strategy for a later line means that some patients may never receive it because of disease progression, declining performance status, or competing treatment needs.

For a patient with a strong predictive biomarker such as BRCA1/2, evidence supporting an appropriate PARPi combination may favour using the combination earlier rather than automatically reserving PARPi therapy for later-line monotherapy.

Conversely, for weaker or less consistently predictive alterations such as ATM, the optimal sequence is less certain. The decision should be regimen- and label-dependent and balanced against standard ARPI, taxane, radiopharmaceutical, or other appropriate treatment options.

Safety and practical treatment selection

  • Haematologic toxicity, particularly anaemia, is an important consideration with PARPi combinations.
  • Dose reductions are common and discontinuation may be required in a minority of patients; the frequency varies considerably between regimens.
  • Toxicity management should follow regimen-specific guidance, with proactive monitoring and dose modification where appropriate to maintain treatment.
  • Where anticipated efficacy is limited or biomarker evidence is weak, tolerability and patient preference should carry greater weight in the treatment decision.

Clinical takeaway

PARPi treatment should be viewed as biomarker- and regimen-specific rather than as a class effect. BRCA1/2 alterations, particularly BRCA2, provide the strongest rationale for PARPi-based treatment. Combination therapy can provide clinically meaningful benefit earlier in the metastatic disease course, but the optimal approach depends on whether the patient has mCSPC or mCRPC, the specific HRR alteration, prior ARPI exposure, the evidence supporting the selected regimen, toxicity considerations, and applicable treatment labels.

Content is accurate as of the date of release.